Jaypirca™ (pirtobrutinib) – New drug approval
January 27, 2023 - Eli Lilly announced the FDA approval of Jaypirca (pirtobrutinib), for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
Top